Get the Stockscreener App
3.019
4.84%
-0.081
Vyome Holdings Inc stock is traded at $3.019, with a volume of 37,335.
It is down -4.84% in the last 24 hours and up +28.26% over the past month.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
See More
Previous Close:
$3.10
Open:
$3.09
24h Volume:
37,335
Relative Volume:
0.05
Market Cap:
$16.65M
Revenue:
$4.19M
Net Income/Loss:
$-11.51M
P/E Ratio:
-0.017
EPS:
-177.3844
Net Cash Flow:
$-3.05M
1W Performance:
-12.20%
1M Performance:
+28.26%
6M Performance:
-62.89%
1Y Performance:
+0.00%
1-Day Range:
$2.88
$3.11
1-Week Range:
$2.88
$3.4459
52-Week Range:
$1.75
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Name
Vyome Holdings Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare HIND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
2.95 | 17.50M | 4.19M | -11.51M | -3.05M | -177.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vyome Holdings Inc Stock (HIND) Latest News
Vyome (HIND) versus Its Rivals Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Peers - Defense World
Financial Contrast: Vyome (HIND) & The Competition - Defense World
HIND Should I Buy - Intellectia AI
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics - TipRanks
Vyome Holdings Unit LiveChain to Acquire $5.8M Humanyze Notes, Issuing 25% Equity to Remus - TradingView
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company - 01net
Livechain completes acquisition of senior, secured debt of Humanyze - marketscreener.com
Reviewing Vyome (HIND) and The Competition - Defense World
Comparing Vyome (NASDAQ:HIND) and Nanovibronix (NASDAQ:FEED) - Defense World
Reviewing Vyome (HIND) & The Competition - Defense World
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Bluefield Daily Telegraph
Critical Survey: Vyome (HIND) & Its Competitors - Defense World
Vyome (HIND) versus Its Competitors Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Competitors - Defense World
Vyome Reports Positive Phase 2 Data for VT-1953 Gel - TipRanks
Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953 - TradingView
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months - The Joplin Globe
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment - Investing.com Nigeria
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment By Investing.com - Investing.com South Africa
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results - BioSpace
Vyome capitalizes all VT-1953 funding requirements for initial phase 3 results - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Penny Stocks To Follow Now – January 27th - Defense World
Recommendations-Union Budget FY27, Vyome Holdings, Inc. - Medical Buyer
Vyome Holdings Highlights VT-1953 Market Potential Analysis - TipRanks
Vyome Holdings, Inc Announces Key Findings on VT-1953 - TradingView
Vyome Holdings Stock Tumults After Strategic Moves in Europe - timothysykes.com
Hindustan Diverges: Financial Snapshot Paints Varied Picture - StocksToTrade
Vyome Holdings Eyes Growth Amid Market Turbulence - timothysykes.com
Vyome stock soars after analyst values lead drug candidate at $1 billion - Investing.com Canada
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study - Business Wire
Vyome (NASDAQ:HIND) and Medline (NASDAQ:MDLN) Critical Survey - Defense World
“Malignant fungating wounds remain significantly under-recognised and under-treated in India” - BioSpectrum India
HIND Forecast — Price Prediction for 2026. Should I Buy HIND? - Intellectia AI
MarketsMedicine Hat NewsMedicine Hat NewsVyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - FinancialContent
Vyome’s LiveChain signs LOI for Humanyze note acquisition - MSN
Vyome Therapeutics2026 Latest Shareholding - Tracxn
Vyome Holdings, Inc. (HIND) Competitors - Meyka
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate - Yahoo Finance
What is the current Price Target and Forecast for Vyome Holdings, Inc. (HIND) - Zacks Investment Research
Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition - TipRanks
Vyome Holdings Signs Letter of Intent With Remus Capital Series B II - TradingView — Track All Markets
Vyome Holdingson Dec 17, Entered Binding L - 富途牛牛
Vyome Subsidiary LiveChain Signs LOI to Take Control of Humanyze Assets - citybiz
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company - Yahoo Finance
Pomichter Stanley D Iii Net Worth (2026) - GuruFocus
Mohanjit Jolly Net Worth (2025) - GuruFocus
Vyome inches towards US FDA approval to enter $1B worth malignant fungating wound market - BioSpectrum India
Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints - MSN
Vyome Holdings Inc Stock (HIND) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):